Skip to content
Back to explorer
Printable monograph

PARP inhibitor

Rucaparib

Rubraca · Ruca

PARP inhibitor · approved 2016 · 7 citations

Up to date· through 2026
Fairly sourced5/9 · 5 signals
  • Met: 7 citations
  • Not met: 12+ references
  • Not met: Accrued over 10+ years (span: 9y)
  • Met: Beyond single case reports
  • Met: High-impact journal
  • Met: Landmark reference
  • Met: Current through 2026
  • Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A PARP inhibitor whose creatinine bump is mostly a transporter artifact, not true kidney injury.

MildPARP inhibitor
Ovarian cancer (maintenance / treatment)BRCA-mutated metastatic castration-resistant prostate cancer

Kidney summary

Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.

Renal dosing
Not in the atlas's table of label-specified renal dose changes; the Dosing section has the full entry.
Hemodialysis
Not removed by hemodialysis
Highly protein-bound; not expected to be appreciably dialyzed and not studied in CrCl<30 or dialysis, so use with caution without an established ESKD dose. PARP inhibitors as a class raise serum creatinine (pooled odds ratio ~5 vs placebo), which may reflect inhibition of tubular creatinine secretion rather than a true fall in GFR — severe renal events were under 1%.PMID 42073552 (opens PubMed in a new tab)
The atlas summary. Full prose in the Dialyzability section.
FDA boxed warning
None on the excerpted label
Label: Rubraca, Oct 2026. FDA label section.
Pseudo-AKI
Documented to raise creatinine by blocking its tubular secretion — an isolated creatinine rise on this agent may be pseudo-AKI, not true injury. Confirm with a cystatin-C-based or measured GFR before holding therapy.
Pseudo-AKI in the injury atlas.
§01

Signature kidney injury

Signature lesion

Representative incidence19.7%

Early reversible serum-creatinine elevation is common and partly drug-specific: rucaparib is a recognized inhibitor of renal cation transporters, and a pooled meta-analysis found markedly higher odds of creatinine rise vs placebo across the class, but grade >=3 renal events were rare (<1%). Reported rate: elevated serum creatinine in 19.7% — Pooled safety population of seven studies of rucaparib monotherapy in patients with recurrent high-grade ovarian… (Adrianto 2024, PMID 39266137).Source: Adrianto et al., Taiwan J Obstet Gynecol 2024

Onset & rechallenge

Time to injurySubacute (~1–6 weeks)

Onset within the first weeks of treatment.

Distilled from: “Within the first weeks of treatment.”

§02

Renal toxicities, ranked

This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

  1. Pseudo-AKI#1 · Signatureno population incidence denominator · drug-level figure in §01

    PARP-inhibitor class (incl. rucaparib): significantly increased serum-creatinine elevation vs placebo (pooled OR 5.04); >=grade 3 renal events <1% — reflects inhibition of tubular creatinine transport, not GFR loss PMID 42073552 (opens PubMed in a new tab)

§03

Kidney injury

Mechanism of kidney injury

Rucaparib inhibits the proximal-tubular cation transporters MATE1, MATE2-K, and OCT2 that secrete creatinine (and also OCT1 and BCRP), raising serum creatinine without a true reduction in glomerular filtration — a transporter-mediated 'pseudo-AKI' rather than tubular injury. True intrinsic nephrotoxicity is uncommon.

Clinical presentation

Asymptomatic mild creatinine increase early in therapy, typically plateauing and reversible; no proteinuria or active sediment. Cystatin C-based eGFR remains at baseline, confirming the transporter mechanism. Transaminase elevation is a separate, common early laboratory effect.

Management

Usually observation; confirm a stable cystatin C before attributing the rise to true AKI or changing dose. Persistent or progressive elevation, proteinuria, or active sediment warrants standard AKI workup and consideration of alternative causes.Lesion-level management framework

Risk factors

  • Pre-existing CKD (lower reserve)
  • Concurrent transporter-inhibiting drugs (e.g. cimetidine, trimethoprim)

Prevention

  • Recognize transporter-mediated pseudo-AKI before acting on the number
  • Use cystatin C-based eGFR when true GFR is uncertain
Anticancer mechanism· how it treats cancer

Inhibits and traps PARP1/2/3 on DNA, producing synthetic lethality in homologous-recombination-deficient (BRCA-mutant) tumors. Used in ovarian cancer and BRCA-mutated metastatic castration-resistant prostate cancer.

§04

Clinical depth

Renal dose adjustment

No starting-dose adjustment for mild-moderate renal impairment (CrCl >=30 mL/min); not studied in CrCl <30 mL/min or dialysis — use with caution. Modest exposure increases occur with moderate impairment but rarely require dose change.

Dialyzability & ESKD dosing

Highly protein-bound small molecule; not expected to be appreciably dialyzed. No established ESKD dosing.

Differential diagnosis

Transporter-mediated pseudo-AKI (stable cystatin C, bland urinalysis, no oliguria) vs true AKI from prerenal causes, ATN, or AIN. A flat cystatin C with a rising creatinine is essentially diagnostic of the transporter effect.

Monitoring

  • Serum creatinine at baseline and each cycle; cystatin C-based eGFR if true GFR is in doubt
  • CBC for anemia/thrombocytopenia/neutropenia
  • Liver enzymes (early transaminase rise is common)

Key trials & series

  • ARIEL3 (recurrent ovarian maintenance)
  • TRITON2 / TRITON3 (BRCA-mutated mCRPC)
  • Gasowska-Bodnar 2026 class creatinine meta-analysis

Clinical pearls

  • Rucaparib raises creatinine by blocking MATE/OCT2 secretion — check cystatin C before calling it AKI or stopping the drug.
  • The creatinine rise appears within weeks, then plateaus and reverses on discontinuation.
  • An early transaminase bump is also expected and usually self-limited — do not conflate it with progressive organ injury.
Where it strikes· nephron segments & injury signatures

Nephron segments

Proximal Tubule

Bulk reabsorption + drug uptake (OCT2, OATs)

Vasculature / Endothelium

Glomerular & peritubular capillaries

Injury signatures

§05

References

7 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

7 references · 2017–2026 · 3 since 2024
202017: 1 citation2020: 1 citation2021: 1 citation2022: 1 citation2024: 2 citations2026: 1 citation201720202026

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

  1. 1.Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysisAdrianto N et al. · Taiwan J Obstet Gynecol · 2024 · PMID 39266137Source of the stored incidence: Hematological concerns comprised anemia (47.9%), thrombocytopenia, elevated AST/ALT (37.3%), and serum creatinine levels (19.7%).
  2. 2.LandmarkPARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Gasowska-Bodnar A et al. · Cancers (Basel) · 2026 · PMID 42073552Pooled RCT analysis showing PARP-inhibitor creatinine elevation likely reflects inhibition of tubular creatinine secretion, not true GFR loss.
  3. 3.Exploring and comparing renal adverse effects between PARP inhibitors based on a real-world analysis of post-marketing surveillance data.Xu Q et al. · Front Med (Lausanne) · 2024 · PMID 39493722Real-world comparison of renal adverse-event signals across individual PARP inhibitors including rucaparib.
  4. 4.Targeted Cancer Therapies Causing Elevations in Serum Creatinine Through Tubular Secretion Inhibition: A Case Report and Review of the Literature.Mach T et al. · Can J Kidney Health Dis · 2022 · PMID 35756332Mechanistic review of targeted-therapy creatinine elevation via tubular-secretion inhibition; cystatin C as confirmatory test.
  5. 5.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.Coleman RL et al. · Lancet · 2017 · PMID 28916367Pivotal ARIEL3 maintenance trial; the registrational safety dataset in which the early reversible creatinine rise is observed.
  6. 6.The forefront of ovarian cancer therapy: update on PARP inhibitors.Mirza MR et al. · Ann Oncol · 2020 · PMID 32569725Class-level efficacy/safety review of the pivotal PARP-inhibitor ovarian trials.
  7. 7.Current Trends in Anti-Cancer Molecular Targeted Therapies: Renal Complications and Their Histological Features.Tonooka A et al. · J Nippon Med Sch · 2021 · PMID 34840210Onconephrology review of renal complications of molecular targeted therapies including small-molecule inhibitors.
FDA label — boxed warning & renal dosing· renal impairment

Quoted verbatim from this agent's current FDA label (Oct 2026) — not paraphrased or interpreted. Full label on DailyMed .

Renal impairment — from the label

No dosage modification is recommended for patients with mild to moderate renal impairment (creatinine clearance [CLcr] between 30 and 89 mL/min, as estimated by the Cockcroft-Gault method) [see Clinical Pharmacology ( 12.3 )]. Rubraca has not been studied in patients with CLcr < 30 mL/min or patients on dialysis.

Kidney rows of the label's dosage tables

From the Rubraca label (Oct 2026) · DailyMed

No row of this label's 2 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 8,832 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

  • Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
  • Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
  • Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.
FAERS reported renal phenotypes· 1 signal

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.

What reporting says about this profile's documented lesions

  • Pseudo-AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
SIADH / Hyponatremia
ROR 1.5295% CI 1.14–2.03· 46 reports· IC025 0.15
FAERS outcomes & reporting trend· 5.9% of reports w/ death · 17.1% w/ hospitalization
5.9%

Reported with a death outcome

517 of 8,832 reports

17.1%

Reported with hospitalization

1,506 of 8,832 reports

Reports per year

  • 2015: 0 reports
  • 2016: 0 reports
  • 2017: 1,452 reports
  • 2018: 1,523 reports
  • 2019: 1,835 reports
  • 2020: 1,442 reports
  • 2021: 1,058 reports
  • 2022: 889 reports
  • 2023: 183 reports
  • 2024: 243 reports
  • 2025: 137 reports
  • 2026: 70 reports

Reports received per year, 2015–2026 · most recent year is partial.

FAERS adverse-event signal — all organ systems· 6 systems · 8,832 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.

Disproportionality (acute kidney injury):ROR 0.7495% CI 0.57–0.95· 61 AKI reports· IC025 −0.82·AKI is reported less often than for other drugs (CI entirely below 1) — no disproportionate signal.
Gastrointestinal
Nausea2,267Diarrhoea791Vomiting787Constipation786Abdominal Pain389
General / constitutional
Fatigue2,553Asthenia681Malaise411Pain296Weight Decreased296
Blood & lymphatic
Anaemia557Platelet Count Decreased539Haemoglobin Decreased359White Blood Cell Count Decreased316
Nervous system
Dysgeusia568Headache439Dizziness409
Metabolic & electrolyte
Decreased Appetite803
Respiratory
Dyspnoea398
Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Rucaparib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.
Phenotype-similar agents· the numbered markers on the map above

Talazoparib

Talzenna · PARP inhibitor

Profile

Renally cleared; creatinine rise.

PSEUDO
Mild#1 · 100% phenotype match

Niraparib

Zejula · PARP inhibitor

Profile

Hypertension and creatinine rise.

HTNPSEUDO
Mild#2 · 76% phenotype match

Olaparib

Lynparza · PARP inhibitor

Profile

Benign creatinine rise via OCT2/MATE inhibition.

PSEUDOTMA
Mild#3 · 76% phenotype match

Larotrectinib

Vitrakvi · TRK inhibitor

Profile

Mild creatinine rise; generally well tolerated.

PSEUDO
Mild#4 · 75% phenotype match

Entrectinib

Rozlytrek · TRK/ROS1 TKI

Profile

Creatinine rise via reduced tubular secretion.

PSEUDO
Mild#5 · 75% phenotype match

Tucatinib

Tukysa · HER2 TKI

Profile

Benign creatinine rise via tubular secretion inhibition.

PSEUDO
Mild#6 · 75% phenotype match
Compare Rucaparib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across PARP inhibitor agents

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.

  1. 1Rucaparib· this agentMild
  2. 1TalazoparibMild
  3. 3NiraparibMild
  4. 3OlaparibMild

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.

Who studies this

The leading contributors to Rucaparib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Rucaparib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.

  1. Pignata, Sandro — their work on Rucaparib, on PubMed (opens in a new tab)2 papers · 36 citesPMID 37668154 (opens PubMed in a new tab)PMID 33099187 (opens PubMed in a new tab)

Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 7 clinical records among all 8 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.